

3. Trimble MR, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. *Mov Disord* 1998;13:617–619.
4. Salloway S, Stewart CF, Israeli L, et al. Botulinum toxin for refractory vocal tics. *Mov Disord* 1996;11:746–748.
5. Adler CH, Zimmerman RS, Lyons MK, Simeone F, Brin MF. Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. *Mov Disord* 1996;11:79–81.
6. Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. *Mov Disord* 1996;11:563–566.
7. Jankovic J. Botulinum toxin in the treatment of dystonic tics. *Mov Disord* 1994;9:347–349.
8. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. *Arch Neurol* 2000;57:1190–1193.

9. Goetz CG, Tanner CM, Wilson RS, Shannon KM. A rating scales for Gilles de la Tourette's syndrome: description, reliability and validity data. *Neurology* 1987;37:1542–1544.
10. Harcherik DF, Leckman JF, Detlor J, Cohen DJ. A new instrument for clinical studies of Tourette's syndrome. *J Am Acad Child Adolesc Psychiatry* 1984;23:153–160.
11. Shapiro AK, Shapiro ES, Young YG, Feinberg TE, eds. *Gilles de la Tourette syndrome*. New York: Raven Press; 1988.
12. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry* 1989;28:566–573.
13. Kurlan R, McDermott MP. Rating tic severity. In: Kurlan R, ed. *Handbook of Tourette's syndrome and related tic and behavioral disorders*. New York: Marcel Dekker; 1993:199–220.

## NeuroImages


### Leukoaraiosis three-dimensional in Binswanger disease

Carlos Valencia, MD, Joan Martí-Fàbregas, MD, Jesús Pujol Nuez, MD, Josep-Lluís Martí-Vilalta, MD, Barcelona, Spain

An 81-year-old man had been hypertensive for years. Three years before this evaluation, he had a stroke and brain imaging showed a left putaminal infarct. During the last 2 years his gait, cognitive abilities, and behavior have gradually deteriorated. On examination, he walked with slow shuffling steps. His Mini-Mental State Examination score was 22. MRI showed severe white matter abnormalities characteristic of Binswanger disease. The white matter abnormalities (leukoaraiosis) in Binswanger disease are most likely caused by chronic ischemia. The most common clinical presentation consists of slowed thinking, walking, and behavior in an elder individual with hypertension.

### References

1. Caplan LR. Binswanger's disease—revisited. *Neurology* 1995; 45:626–633.
2. Blass JP, Hoyer S, Nitsch R. A translation of Otto Binswanger's article: the delineation of the generalized progressive paralysis. *Arch Neurol* 1991;48:961–972.



*Figure. (A) On T1-weighted MRI, the white matter abnormalities are not well shown. Proton density images (B) show prominent white matter hyperintensities. C and D are three-dimensional images that show white matter lesions (light brown) located predominantly in the frontal and parietal lobes adjacent to the lateral ventricles.*

# Neurology<sup>®</sup>

**Leukoaraiosis three-dimensional in Binswanger disease**  
Carlos Valencia, Joan Martí-Fàbregas, Jesús Pujol Nuez, et al.  
*Neurology* 2001;56;610  
DOI 10.1212/WNL.56.5.610

**This information is current as of March 13, 2001**

|                                           |                                                                                                                                                                                                                                                             |
|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Updated Information &amp; Services</b> | including high resolution figures, can be found at:<br><a href="http://n.neurology.org/content/56/5/610.full">http://n.neurology.org/content/56/5/610.full</a>                                                                                              |
| <b>References</b>                         | This article cites 2 articles, 1 of which you can access for free at:<br><a href="http://n.neurology.org/content/56/5/610.full#ref-list-1">http://n.neurology.org/content/56/5/610.full#ref-list-1</a>                                                      |
| <b>Permissions &amp; Licensing</b>        | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:<br><a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a> |
| <b>Reprints</b>                           | Information about ordering reprints can be found online:<br><a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>                                                                                         |

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

